These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 21416169)

  • 21. Adiponectin and interleukin-6, but not adipose tissue, are associated with worse neurocognitive function in HIV-infected men.
    Lake JE; Vo QT; Jacobson LP; Sacktor N; Miller EN; Post WS; Becker JT; Palella FJ; Ragin A; Martin E; Munro CA; Brown TT
    Antivir Ther; 2015; 20(2):235-44. PubMed ID: 25810377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disparities in Initiation of Combination Antiretroviral Treatment and in Virologic Suppression Among Patients in the HIV Outpatient Study, 2000-2013.
    Novak RM; Hart RL; Chmiel JS; Brooks JT; Buchacz K;
    J Acquir Immune Defic Syndr; 2015 Sep; 70(1):23-32. PubMed ID: 25886926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical factors related to brain structure in HIV: the CHARTER study.
    Jernigan TL; Archibald SL; Fennema-Notestine C; Taylor MJ; Theilmann RJ; Julaton MD; Notestine RJ; Wolfson T; Letendre SL; Ellis RJ; Heaton RK; Gamst AC; Franklin DR; Clifford DB; Collier AC; Gelman BB; Marra C; McArthur JC; McCutchan JA; Morgello S; Simpson DM; Grant I;
    J Neurovirol; 2011 Jun; 17(3):248-57. PubMed ID: 21544705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings.
    Cherner M; Ellis RJ; Lazzaretto D; Young C; Mindt MR; Atkinson JH; Grant I; Heaton RK;
    AIDS; 2004 Jan; 18 Suppl 1():S27-34. PubMed ID: 15075495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cognitive disorders in HIV-infected patients: are they HIV-related?
    Bonnet F; Amieva H; Marquant F; Bernard C; Bruyand M; Dauchy FA; Mercié P; Greib C; Richert L; Neau D; Catheline G; Dehail P; Dabis F; Morlat P; Dartigues JF; Chêne G;
    AIDS; 2013 Jan; 27(3):391-400. PubMed ID: 23079813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peripheral biomarkers do not correlate with cognitive impairment in highly active antiretroviral therapy-treated subjects with human immunodeficiency virus type 1 infection.
    Sun B; Abadjian L; Rempel H; Calosing C; Rothlind J; Pulliam L
    J Neurovirol; 2010 Mar; 16(2):115-24. PubMed ID: 20307252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of polymorphisms in the HCP5 and HLA-C, and ZNRD1 genes on HIV viral load.
    Thørner LW; Erikstrup C; Harritshøj LH; Larsen MH; Kronborg G; Pedersen C; Larsen CS; Pedersen G; Gerstoft J; Obel N; Ullum H
    Infect Genet Evol; 2016 Jul; 41():185-190. PubMed ID: 27083073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease.
    Letendre SL; Cherner M; Ellis RJ; Marquie-Beck J; Gragg B; Marcotte T; Heaton RK; McCutchan JA; Grant I;
    AIDS; 2005 Oct; 19 Suppl 3():S72-8. PubMed ID: 16251831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors.
    Heaton RK; Franklin DR; Ellis RJ; McCutchan JA; Letendre SL; Leblanc S; Corkran SH; Duarte NA; Clifford DB; Woods SP; Collier AC; Marra CM; Morgello S; Mindt MR; Taylor MJ; Marcotte TD; Atkinson JH; Wolfson T; Gelman BB; McArthur JC; Simpson DM; Abramson I; Gamst A; Fennema-Notestine C; Jernigan TL; Wong J; Grant I; ;
    J Neurovirol; 2011 Feb; 17(1):3-16. PubMed ID: 21174240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regional areas and widths of the midsagittal corpus callosum among HIV-infected patients on stable antiretroviral therapies.
    Tate DF; Sampat M; Harezlak J; Fiecas M; Hogan J; Dewey J; McCaffrey D; Branson D; Russell T; Conley J; Taylor M; Schifitto G; Zhong J; Daar ES; Alger J; Brown M; Singer E; Campbell T; McMahon D; Tso Y; Matesan J; Letendre S; Paulose S; Gaugh M; Tripoli C; Yiannoutsos C; Bigler ED; Cohen RA; Guttmann CR; Navia B;
    J Neurovirol; 2011 Aug; 17(4):368-79. PubMed ID: 21556960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors.
    Tozzi V; Balestra P; Bellagamba R; Corpolongo A; Salvatori MF; Visco-Comandini U; Vlassi C; Giulianelli M; Galgani S; Antinori A; Narciso P
    J Acquir Immune Defic Syndr; 2007 Jun; 45(2):174-82. PubMed ID: 17356465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy.
    Ellis RJ; Badiee J; Vaida F; Letendre S; Heaton RK; Clifford D; Collier AC; Gelman B; McArthur J; Morgello S; McCutchan JA; Grant I;
    AIDS; 2011 Sep; 25(14):1747-51. PubMed ID: 21750419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuropsychological Impairment in Acute HIV and the Effect of Immediate Antiretroviral Therapy.
    Kore I; Ananworanich J; Valcour V; Fletcher JL; Chalermchai T; Paul R; Reynolds J; Tipsuk S; Ubolyam S; Rattanamanee S; Jagodzinski L; Kim J; Spudich S;
    J Acquir Immune Defic Syndr; 2015 Dec; 70(4):393-9. PubMed ID: 26509933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of symptomatic HIV-associated neurocognitive disorders in universal health care.
    McCombe JA; Vivithanaporn P; Gill MJ; Power C
    HIV Med; 2013 Feb; 14(2):99-107. PubMed ID: 22994556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic shift of env V3 loop viral sequences in patients with HIV-associated neurocognitive disorder during antiretroviral therapy.
    Eggers C; Müller O; Thordsen I; Schreiber M; Methner A
    J Neurovirol; 2013 Dec; 19(6):523-30. PubMed ID: 24101298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy.
    Garvey L; Surendrakumar V; Winston A
    HIV Clin Trials; 2011; 12(6):333-8. PubMed ID: 22189152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prevalence and incidence of neurocognitive impairment in the HAART era.
    Robertson KR; Smurzynski M; Parsons TD; Wu K; Bosch RJ; Wu J; McArthur JC; Collier AC; Evans SR; Ellis RJ
    AIDS; 2007 Sep; 21(14):1915-21. PubMed ID: 17721099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determining optimal impairment rating methodology for a new HIV-associated neurocognitive disorder screening procedure.
    Kamminga J; Bloch M; Vincent T; Carberry A; Brew BJ; Cysique LA
    J Clin Exp Neuropsychol; 2017 Oct; 39(8):753-767. PubMed ID: 28052738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A screening algorithm for HIV-associated neurocognitive disorders.
    Cysique LA; Murray JM; Dunbar M; Jeyakumar V; Brew BJ
    HIV Med; 2010 Nov; 11(10):642-9. PubMed ID: 20456505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis B virus prevalence and vaccine response in HIV-infected children and adolescents on combination antiretroviral therapy in Kigali, Rwanda.
    Mutwa PR; Boer KR; Rusine JB; Muganga N; Tuyishimire D; Reiss P; Lange JM; Geelen SP
    Pediatr Infect Dis J; 2013 Mar; 32(3):246-51. PubMed ID: 22976050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.